Testosterone / Hormone Therapy Denied by Insurance? How to Appeal
Insurance denied testosterone replacement therapy (TRT) for hypogonadism, or hormone therapy for menopause? Learn how to appeal a hormone therapy denial. Free guide.
Hormone therapy denials — whether for testosterone replacement therapy (TRT) in men with hypogonadism or hormone replacement therapy (HRT) for menopausal women — are common and often reversible on appeal. Here's how to fight back.
Testosterone Replacement Therapy (TRT) Denials
Why Insurers Deny TRT
Testosterone level doesn't meet threshold. Most PA criteria require a morning serum total testosterone below a specific threshold (commonly <300 ng/dL or <200 ng/dL), with the measurement taken on two separate occasions before 10 AM.
Only one lab value, not two. Plans often require two confirmatory testosterone measurements (on separate days, both morning draws) before approving TRT.
Symptoms not documented. In addition to low testosterone levels, PA criteria typically require at least 3 classic hypogonadism symptoms: decreased libido, erectile dysfunction, fatigue, decreased muscle mass, increased body fat, depressed mood, decreased bone density, or reduced body/facial hair.
Age-related decline ("andropause") denied. Insurers may deny TRT for age-related testosterone decline without a formal hypogonadism diagnosis, even when levels are below normal range.
"Lifestyle modification required first." Some plans require documentation that obesity, alcohol, or medication causes have been addressed.
Non-preferred formulation. Generic testosterone (gels, injections) are preferred; branded products (AndroGel, Testim, Axiron, Aveed) often require step through generic.
TRT Covered Indications
FDA-approved indications for testosterone replacement:
- Male hypogonadism: Congenital (primary — testicular failure; Klinefelter syndrome, anorchia) or acquired (pituitary tumor, surgery, radiation, chemotherapy, infection)
- Delayed puberty in males: Short-term, physician-supervised
Off-label but medically supported:
- Age-related hypogonadism when symptomatic and with consistently low testosterone
- Hypogonadism in HIV/AIDS patients
- Chemotherapy/radiation-induced hypogonadism
Building Your TRT Appeal
Required documentation:
- Two morning testosterone levels (before 10 AM, fasting recommended): total testosterone <300 ng/dL (or per plan threshold); free testosterone calculation
- LH and FSH levels (to distinguish primary vs. secondary hypogonadism)
- Symptom documentation: Formal symptom questionnaire (ADAM score, AMS scale) documenting ≥3 classic hypogonadism symptoms
- Prolactin and pituitary MRI if secondary hypogonadism suspected (elevated prolactin)
- Physician letter from endocrinologist, urologist, or internist diagnosing hypogonadism and prescribing TRT with clinical rationale
Endocrine Society Guidelines (2018): Recommend TRT for men with classic symptoms of hypogonadism AND consistently low total testosterone levels. Provide a copy of this guideline excerpt.
Step therapy for formulation:
- If generic testosterone cypionate/enanthate injection is required first: document failed attempt or reason for preference (e.g., compliance issues with injections, skin reactions to generic gel, transfer risk in household with children)
- Topical gels have transfer risk to women/children — document household composition
Hormone Replacement Therapy (HRT) for Menopause
Why Insurers Deny Menopause HRT
"Not medically necessary." Many insurers consider menopausal hormone therapy elective, despite its role in treating vasomotor symptoms, genitourinary syndrome of menopause (GSM), and osteoporosis prevention.
Bioidentical hormones not covered. FDA-approved bioidentical estrogens (estradiol, progesterone) are covered; compounded bioidentical hormones are almost never covered.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Osteoporosis indication denied separately. HRT for bone protection after menopause may require documented osteoporosis (T-score ≤-2.5) or osteopenia with high fracture risk.
Duration limits exceeded. Some plans limit HRT to 1–2 years.
HRT Clinical Arguments
NAMS (North American Menopause Society) Position Statement 2022:
- For healthy women under 60 or within 10 years of menopause, benefits of HRT outweigh risks for treatment of vasomotor symptoms
- HRT is first-line therapy for moderate-to-severe menopause symptoms
- Lowest effective dose for shortest appropriate duration is the clinical standard
Vasomotor symptoms (hot flashes, night sweats): These are a documented medical condition, not cosmetic. Severe vasomotor symptoms impair sleep, work performance, and quality of life.
Genitourinary syndrome of menopause (GSM): Vaginal dryness, urogenital atrophy, dyspareunia, and urinary urgency — local estrogen therapy (Vagifem, Estrace cream, Imvexxy) is effective and appropriate.
Osteoporosis prevention: Estrogen significantly reduces fracture risk in postmenopausal women. If the patient has risk factors for osteoporosis, HRT can be medically necessary for bone protection.
Gender-Affirming Hormone Therapy Denials
Hormone therapy for transgender individuals — estradiol and anti-androgens for trans women; testosterone for trans men — is increasingly covered under ACA non-discrimination rules.
ACA Section 1557: Prohibits sex discrimination in health insurance, which courts have interpreted to include gender identity. Denials of gender-affirming hormone therapy on grounds of "not medically necessary" or "cosmetic" can be challenged under Section 1557.
WPATH Standards of Care (Version 8, 2022): Hormone therapy is recommended for gender dysphoria based on informed consent — no longer requires surgery or gatekeeping requirements. Cite SOC-8 in appeals.
State laws: Many states have enacted explicit transgender health protection laws prohibiting discriminatory coverage exclusions.
Sample Appeal Language (TRT)
"I am appealing the denial of testosterone replacement therapy for hypogonadism. Two morning serum testosterone measurements confirmed total testosterone of [X ng/dL, date] and [Y ng/dL, date], both below the 300 ng/dL threshold. My patient is experiencing [list symptoms: decreased libido, fatigue, erectile dysfunction, reduced muscle mass] consistent with hypogonadal symptoms.
Endocrine Society Clinical Practice Guidelines (2018) recommend TRT for men with consistently low testosterone and classic hypogonadism symptoms. This therapy is medically necessary for treatment of documented hypogonadism. I respectfully request reversal of this denial."
Fight Back With ClaimBack
ClaimBack generates hormone therapy appeal letters citing Endocrine Society and NAMS guidelines, documentation requirements for hypogonadism, and ACA non-discrimination arguments for gender-affirming care.
Free analysis. Appeal letter from USD 12.
Related Reading
- What Is Medical Necessity and How to Prove It
- Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Denied? How to Appeal
- How to Write an Insurance Appeal Letter That Works
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides